United Therapeutics shareholders approve 2026 stock incentive plan at annual meeting

United Therapeutics Corporation held its 2026 Annual Meeting of Shareholders on June 26, 2026, according to an 8-K filed with the SEC. Shareholders considered four matters, each described in more detail in the proxy statement.¹

Shareholders approved the United Therapeutics Corporation 2026 Stock Incentive Plan, which had already received board approval on the recommendation of the compensation committee.¹ The plan's effective date is June 26, 2026.¹ The company said the plan's purpose is to stimulate the efforts of non-employee directors, officers, employees, and other service providers selected to participate, by heightening their desire to continue contributing to the company's success and progress.¹

Under the plan's share reserve mechanics, the total shares issuable equal the shares still available under the prior 2015 plan as of the effective date plus 1,500,000 new shares, plus any prior-plan awards that are later canceled, expired, forfeited, or settled in cash rather than issued.¹ As a reference point, the filing disclosed that as of June 26, 2026, 2,413,730 shares remained available for future grant under the prior plan, and 4,941,655 shares were subject to outstanding awards under that plan.¹

The vote tally on Proposal 3 showed 25,872,075 votes for the new plan, 10,070,290 against, and 276,512 abstentions.¹ All twelve director nominees, including Martine Rothblatt and Ray Kurzweil, were reelected.¹ The advisory vote on executive compensation passed with 35,152,059 votes in favor.¹ Shareholders also ratified Ernst & Young LLP as the company's independent registered public accounting firm for 2026, with 35,753,887 votes in support.¹